1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Mean CBF and mean nCBF values in the lesions at different stages and control group findings
Stage (Days)No. of CasesRange of CBF Values (mL/100g/min)Mean CBF Values (mL/100g/min)Mean nCBF Values
Acute stage (≤14)1159.5–162.3121.5 ± 33.82.68 ± 0.54
Subacute stage (15–25)666.1–126.598.3 ± 22.82.42 ± 0.52
Chronic stage (≥26)623.0–63.133.9 ± 15.00.87 ± 0.30
Control groupa1547.9–71.958.8 ± 7.01.33 ± 0.08
  • ↵a The temporal cortex perfusion as a control reference.